Table 2.
Baseline demographic and clinical characteristics by region
| USA (n=119) | Uganda (n=161) | Russia (n=192) | All other (n=103) | |
|---|---|---|---|---|
| Age (years) | 42 (34–49) | 31 (34–49) | 33 (28–39) | 37 (30–44) |
|
| ||||
| HIV-1 RNA (log10 copies per mL) | 4·18 (3·60–4·82) | 4·43 (4·16–5·02) | 4·63 (4·27–5·07) | 4·55 (3.97–4·99) |
|
| ||||
| HIV-1 subtype (≥10%) | B (90%) | A1 (45%), D (28%) | A1 (55%), A (32%) | B (31%), AE (24%), AG (12%), C (11%) |
|
| ||||
| CD4 cell count (cells per μL) | 387 (264–567) | 396 (258–520) | 317 (237–436) | 343 (244–427) |
|
| ||||
| Positive HBsAg | 5 (8%) | 5 (3%) | 4 (2%) | 2 (2%) |
|
| ||||
| Positive HCV antibody | 9 (10%) | 2 (1%) | 32 (18%) | 4 (4%) |
|
| ||||
| BMI (kg/m2) | 29·5 (25·2–36·0) | 23·8 (20·8–27·2) | 23·1 (20·8, 25·5) | 25·6 (22·2, 30·1) |
|
| ||||
| Estimated GFR (mL/min) | 116·9 (92·2–150·1) | 98·4 (84·0, 113·4) | 107·4 (93·0–122·4) | 111·0 (99·0–131·4) |
|
| ||||
| HIV risk (%) | ||||
| Heterosexual | 112 (94%) | 160 (99%) | 172 (90%) | 101 (98%) |
| Intravenous drug use | 3 (3%) | 0 | 16 (8%) | 0 |
| Transfusion | 4 (3%) | 0 | 0 | 2 (2%) |
|
| ||||
| HIV disease status | ||||
| Asymptomatic | 96 (81%) | 135 (84%) | 131 (68%) | 87 (85%) |
| Symptomatic | 8 (7%) | 26 (16%) | 58 (30%) | 9 (8%) |
| AIDS | 15 (13%) | 0 | 3 (2%) | 7 (7%) |
|
| ||||
| Race | ||||
| Black | 84 (71%) | 161 (100%) | 0 | 31 (30%) |
| White | 31 (26%) | 0 | 192 (100%) | 24 (23%) |
| Asian | 2 (2%) | 0 | 0 | 24 (23%) |
| Other | 1 (1%) | 0 | 0 | 23 (22%) |
Data are median or n (%). Integrase inhibitor regimen was elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate; protease inhibitor regimen was ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate. HBsAg=hepatitis B surface antigen. HCV=hepatitis C virus. BMI=body-mass index. GFR=glomerular filtration rate.